Search terms
Results 1 - 10 of 57 - ordered by :
Pages: 1 2 3 4 5 6 ... 6

Nationwide register dataMyocardial infarctionRisk factorsPrognosisMortality See page 1155 for the editorial comment on this article (doi:10.1093/eurheartj/ehv048) Clinical perspective This ...

European Heart Journal, Acute coronary syndrome, Tomas Jernberg, PÃ¥l Hasvold, Martin Henriksson, Hans Hjelm, Marcus Thuresson, Magnus Janzon

Date : 14/05/2015 Item size : 313858 bytes

Unfortunately, gastrointestinal bleeding in patients after acute coronary syndrome portends poor prognosis and is independently associated with increased risk for adverse cardiovascular events and ...

European Heart Journal - Cardiovascular Pharmacotherapy, INVITED EDITORIAL, Muthiah Vaduganathan, Deepak L. Bhatt

Date : 01/01/2016 Item size : 163944 bytes

Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus Nikolaus Marx, Darren K. McGuire European Heart Journal Nov 2016, 37 ...

European Heart Journal, Review, Nikolaus Marx, Darren K. McGuire

Date : 07/11/2016 Item size : 159932 bytes

In their trial, Cannon et al. report the superiority of the anti-PCSK9 monoclonal antibody (mAb) alirocumab (SAR236553/REGN727; s.c. 75 mg every 2 weeks) over ezetimibe (oral 10 mg once a day) in the ...

European Heart Journal, Editorial, Baris Gencer, François Mach

Date : 14/05/2015 Item size : 244342 bytes

Download the Issue @ a Glance podcast Subscribe to the EHJ Podcast Prevention is better that cure As Niccolo Machiavelli already pointed out in his seminal work Il Principe in 1513, any disease is ...

European Heart Journal, ISSUE @ A GLANCE, Thomas F. Lüscher

Date : 14/05/2015

Abstract Aims Recent trials have examined the effect of prolonged dual antiplatelet therapy (DAPT) in a variety of patient populations, with heterogeneous results regarding benefit and safety, ...

European Heart Journal, FASTTRACK CLINICAL RESEARCH, Jacob A. Udell, Marc P. Bonaca, Jean-Philippe Collet, A. Michael Lincoff, Dean J. Kereiakes, Francesco Costa, Cheol Whan Lee, Laura Mauri, Marco ...

Date : 21/01/2016

Furthermore, the EMPA-REG OUTCOME trial using the novel antihyperglycaemic agent, empagliflozin,8 a selective sodiumglucose co- transporter inhibitor, significantly reduced cardiovascular mortality; ...

European Heart Journal, ISSUE @ A GLANCE, Thomas F. Lüscher

Date : 07/02/2016

Notably, this includes (i) event reduction in high-risk patients in general practice following introduction of a comprehensive strategy to attenuate modifiable risk factors, including lifestyle and ...

European Heart Journal, CURRENT OPINION, M. John Chapman, Stefan Blankenberg, Ulf Landmesser

Date : 07/02/2016

First published by Oxford University Press on behalf of the European Society of Cardiology in European Heart Journal [Eur Heart J. 2016 Feb 7;37(6):510-9]. Notably, this includes (i) event reduction ...

Date : 01/02/2017

2 , Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

European Heart Journal, Wong, K.Y.K., Macwalter, R.S., Fraser, H.W., Crombie, I., Ogston, S.A., Struthers, A.D.

Date : 01/05/2002 Item size : 130321 bytes